Log in
Enquire now
‌

US Patent 12059452 Fusion proteins

Patent 12059452 was granted and assigned to Eli Lilly and Company on August, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Eli Lilly
Eli Lilly
0
Date Filed
January 18, 2022
0
Date of Patent
August 13, 2024
0
Patent Applicant
Eli Lilly
Eli Lilly
0
Patent Application Number
17577932
0
Patent Citations
‌
US Patent 9018161 Protease resistant insulin analogues
0
‌
US Patent 9260502 Protease-stabilized insulin analogues
0
‌
US Patent 9260501 Peptide extended insulins
0
‌
US Patent 7271149 GLP-1 fusion proteins
0
‌
US Patent 7323543 Multiple agent diabetes therapy
0
‌
US Patent 7452966 GLP-1 analog fusion proteins
0
‌
US Patent 8501440 Fibrillation-resistant insulin and insulin analogues
0
‌
US Patent 8883449 Single-chain insulin
0
Patent Inventor Names
Andrew Ihor Korytko
0
Gregory Alan Lazar
0
David Bruce Baldwin
0
John Michael Beals
0
Craig Duane Dickinson
0
Jonathan Wesley Day
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12059452
0
Patent Primary Examiner
‌
Gyan Chandra
0
CPC Code
‌
A61P 3/10
0
‌
C07K 14/62
0
‌
A61K 38/16
0
‌
A61K 38/28
0

Find more entities like US Patent 12059452 Fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us